WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H598254
CAS#: 144412-49-7 (free base)
Description: Lamifiban, also known as Ro 44-9883, is a platelet glycoprotein IIb/IIIa inhibitor or platelet aggregation inhibitor, Lamifiban prevents platelet loss during experimental cardiopulmonary bypass. Lamifiban inhibits platelet aggregation and thrombus formation by preventing the binding of fibrinogen to platelets.
Hodoodo Cat#: H598254
Name: Lamifiban
CAS#: 144412-49-7 (free base)
Chemical Formula: C24H28N4O6
Exact Mass: 468.20
Molecular Weight: 468.510
Elemental Analysis: C, 61.53; H, 6.02; N, 11.96; O, 20.49
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 144412-50-0 (TFA) 144412-49-7 (free base)
Synonym: Lamifiban; Ro 44-9883/000; Ro-44-9883/000; Ro44-9883/000; Ro 44-9883; Ro-44-9883; Ro44-9883; Ro 449883; Ro-449883; Ro449883;
IUPAC/Chemical Name: 2-((1-((4-carbamimidoylbenzoyl)-L-tyrosyl)piperidin-4-yl)oxy)acetic acid
InChi Key: FPKOGTAFKSLZLD-FQEVSTJZSA-N
InChi Code: InChI=1S/C24H28N4O6/c25-22(26)16-3-5-17(6-4-16)23(32)27-20(13-15-1-7-18(29)8-2-15)24(33)28-11-9-19(10-12-28)34-14-21(30)31/h1-8,19-20,29H,9-14H2,(H3,25,26)(H,27,32)(H,30,31)/t20-/m0/s1
SMILES Code: O=C(O)COC1CCN(C([C@H](CC2=CC=C(O)C=C2)NC(C3=CC=C(C(N)=N)C=C3)=O)=O)CC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 468.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Global Organization Network (PARAGON)-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation. 2002 Jan 22;105(3):316-21. PubMed PMID: 11804986.
2: Dooley M, Goa KL. Lamifiban. Drugs. 1999 Feb;57(2):215-21; discussion 222-3. Review. PubMed PMID: 10188762.
3: Théroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation. 1996 Sep 1;94(5):899-905. PubMed PMID: 8790023.
4: Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol. 1998 Dec;32(7):2003-10. PubMed PMID: 9857885.
5: International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation. 1998 Jun 23;97(24):2386-95. PubMed PMID: 9641689.
6: Frojmovic M, Labarthe B, Legrand C. Inhibition and reversal of platelet aggregation by alphaIIbbeta3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban. Br J Haematol. 2005 Nov;131(3):348-55. PubMed PMID: 16225655.
7: Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffmann AH, Chou RC. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol. 1996 Jun;48(6):573-7. PubMed PMID: 8832489.
8: Lehne G, Nordal KP, Midtvedt K, Goggin T, Brosstad F. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction. Thromb Haemost. 1998 Jun;79(6):1119-25. PubMed PMID: 9657435.
9: Lamifiban. Drugs R D. 1999 May;1(5):379-82. PubMed PMID: 10566069.
10: Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Van De Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation. 2001 Jun 19;103(24):2891-6. PubMed PMID: 11413076.
11: McBane RD 2nd, Karnicki K, Wysokinski WE. Platelet recruitment to venous stent thrombi. J Thromb Thrombolysis. 2013 Nov;36(4):442-7. doi: 10.1007/s11239-013-0924-x. PubMed PMID: 23595514.
12: Moliterno DJ, Harrington RA, Califf RM, Rapold HJ, Topol EJ. Randomized, Placebo-Controlled Study of Lamifiban with Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction: Rationale and Design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Study. J Thromb Thrombolysis. 1995;2(3):165-169. PubMed PMID: 10608020.
13: Alexander JH, Harrington RA. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Drugs. 1998 Dec;56(6):965-76. Review. PubMed PMID: 9878986.
14: Gomes N, Vassy J, Lebos C, Arbeille B, Legrand C, Fauvel-Lafeve F. Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: effects of alphavbeta3 and alphaIIbbeta3 antagonists. Clin Exp Metastasis. 2004;21(6):553-61. PubMed PMID: 15679053.
15: Chico TJ, Chamberlain J, Gunn J, Arnold N, Bullens SL, Gadek TR, Francis SE, Bunting S, Horton M, Shepherd L, Lipari MT, Quan C, Knolle J, Stilz HU, Peyman A, Crossman DC. Effect of selective or combined inhibition of integrins alpha(IIb)beta(3) and alpha(v)beta(3) on thrombosis and neointima after oversized porcine coronary angioplasty. Circulation. 2001 Feb 27;103(8):1135-41. PubMed PMID: 11222478.
16: Starnes HB, Patel AA, Stouffer GA. Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions. Drugs. 2011 Oct 22;71(15):2009-30. doi: 10.2165/11595010-000000000-00000. Review. PubMed PMID: 21985168.
17: André P, Arbeille B, Drouet V, Hainaud P, Bal dit Sollier C, Caen JP, Drouet LO. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig. Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):56-63. PubMed PMID: 8548427.
18: Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J. 2002 Dec;144(6):995-1002. PubMed PMID: 12486423.
19: Barrabés JA, Garcia-Dorado D, Mirabet M, Lidón RM, Soriano B, Ruiz-Meana M, Pizcueta P, Blanco J, Puigfel Y, Soler-Soler J. Lack of effect of glycoprotein IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs. J Am Coll Cardiol. 2002 Jan 2;39(1):157-65. PubMed PMID: 11755302.
20: André P, Hainaud P, Bal dit Sollier C, Garfinkel LI, Caen JP, Drouet LO. Relative involvement of GPIb/IX-vWF axis and GPIIb/IIIa in thrombus growth at high shear rates in the guinea pig. Arterioscler Thromb Vasc Biol. 1997 May;17(5):919-24. PubMed PMID: 9157956.
